Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dechra Pharmaceuticals
Type Public (LSEDPH)
Industry Pharmaceuticals
Founded 1997
Headquarters Stoke-on-Trent, England
Key people Michael Redmond, (Chairman)
Ian Page, (CEO)
Products Felimazola, Vetoryl
Revenue £189.2 million (2013)1
Operating income £39.1 million (2013)1
Net income £17.9 million (2013)1
Website www.dechra.com

Dechra Pharmaceuticals plc is an English-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.2 It was first listed on the London Stock Exchange in 2000.2 In 2007 it bought VetXX, a Danish veterinary products business, for £62m.3 It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.4

Operations

The Company sells pharmaceuticals - mainly for dogs, cats and horses; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.5

See also

References








Creative Commons License